Fi­bro­Gen shares take a beat­ing as CEO re­veals safe­ty da­ta ma­nip­u­la­tion for its block­buster con­tender rox­adu­s­tat

Fi­bro­Gen $FGEN back­tracked on some of the key safe­ty da­ta used to boost hopes for their ane­mia drug rox­adu­s­tat, elim­i­nat­ing its claim of su­pe­ri­or­i­ty over …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.